Stroke
RSSArticles
-
Should Aspirin Be Used for Primary Prevention of Cardiovascular Events?
Primary prevention of cardiovascular disease and death by using daily low-dose aspirin is not recommended and should be reserved for those instances in which secondary prevention has been demonstrated to be effective in randomized clinical trials.
-
Ultraearly Intravenous Thrombolysis for Acute Ischemic Stroke
-
Thrombolysis for ‘Wake-up’ Stroke
-
Dual Antiplatelet Therapy for Acute Ischemic Stroke and TIA
-
Treatment of Chronic Subdural Hematoma With Atorvastatin
-
Atrial Flutter, Atrial Fibrillation, and Ischemic Stroke
-
Recanalization Treatment in Pediatric Arterial Ischemic Stroke
In a population-based study from Switzerland, the authors found that recanalization treatment (intravenous thrombolysis or endovascular treatment) overall was safe without significant side effects or increased mortality compared to standard care.
-
Dual Antiplatelet Therapy for Minor Ischemic Stroke or TIA
These investigators undertook this study to evaluate the effect of clopidogrel plus aspirin, vs. aspirin alone, in an international population of patients who had minor ischemic stroke or TIA — Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT).
-
Tenecteplase vs. Alteplase for Ischemic Stroke
In a recent trial, treatment with tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase if administered to patients with ischemic stroke within 4.5 hours of symptom onset.
-
Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft
The data from this study do not indicate that new-onset postoperative atrial fibrillation should be regarded as having the same risks as primary nonvalvular atrial fibrillation in terms of long-term thromboembolic risk, and that anticoagulation in this group may not be necessary unless the atrial fibrillation is persistent.